RT Book, Section
A1 Garvey, W. Timothy
A1 Mechanick, Jeffrey I.
A2 Fuster, Valentin
A2 Narula, Jagat
A2 Vaishnava, Prashant
A2 Leon, Martin B.
A2 Callans, David J.
A2 Rumsfeld, John
A2 Poppas, Athena
SR Print(0)
ID 1202441966
T1 Cardiometabolic Disease: Insulin Resistance, Obesity, and the Metabolic Syndrome
T2 Fuster and Hurst's The Heart, 15e
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264257560
LK accesscardiology.mhmedical.com/content.aspx?aid=1202441966
RD 2023/12/06
AB Chapter  SummaryThis  chapter  discusses  the  pathophysiology  and  treatment  of  cardiometabolic  disease  and  obesity.  Insulin  resistance  is  at  the  core  of  the  pathophysiology  of  cardiometabolic  disease  and  can  give  rise  to  metabolic  syndrome,  prediabetes,  and  non-alcoholic  fatty  liver  disease  (NAFLD)  (see  Fuster  and  Hurst’s  Central  Illustration).  Patients  with  insulin  resistance,  metabolic  syndrome,  and/or  prediabetes  have  accelerated  atherogenesis  and  increased  risk  for  cardiovascular  disease  (CVD).  Prediabetes  and  NAFLD  can  progress  to  type  2  diabetes  and  non-alcoholic  steatohepatitis  (NASH),  respectively;  these  conditions  further  amplify  the  progression  of  vascular  disease  and  risk  of  CVD  events.  Obesity  can  exacerbate  insulin  resistance  and  promote  cardiometabolic  disease  progression,  but  it  can  also  exist  independent  of  cardiometabolic  disease.  In  the  prevention  and  treatment  of  cardiometabolic  disease,  intervention  should  be  early  and  encompass  metabolic  and  vascular  outcomes.  Healthy  meal  plans,  aerobic  and  resistance  exercise,  and  aggressive  surveillance  and  management  of  CVD  risk  factors  are  all  warranted.  A  chronic  care  model  for  cardiometabolic  disease  should  be  an  integral  component  of  health-care  systems.